S. Michael Owens, Ph.D.
Chief Scientific Officer (CSO)
Professor and Director, Center for Alcohol and Drug Abuse, and a
Wilbur Mills Endowed Chair in Alcohol and Drug Abuse Prevention
and Arkansas Research Alliance Fellow, University of Arkansas for Medical Sciences
S. Michael Owens, PhD, the Company’s Chief Scientific Officer, is a Professor of Pharmacology and Toxicology and holds a Wilbur Mills Endowed Chair in Alcohol and Drug Abuse Studies at UAMS. Dr. Owens has expertise in pharmacokinetics, pharmacodynamics and immunopharmacology with extensive experience in vaccine design and the development of therapeutic monoclonal antibodies. He pioneered the research and development of the therapeutic antibodies and vaccines for drug abuse that are the foundation for InterveXion.
W. Brooks Gentry, MD
Chief Medical Officer (CMO)
Professor and Chair, Department of Anesthesiology
Professor of Pharmacology & Toxicology
University of Arkansas for Medical Sciences
InterveXion’s Chief Medical Officer is W. Brooks Gentry, MD, who is currently a Professor of Anesthesiology and Pharmacology & Toxicology, and Chair of the Department of Anesthesiology in the College of Medicine at UAMS. Dr. Gentry brings expertise in clinical trial design for therapeutic biologics, including monoclonal antibodies. He has performed human clinical and basic science research on drugs that affect the central nervous system (brain and spinal cord) since 1991.
Ralph Henry, Ph.D.
Vice President of Biopharmaceutics
Dr. Henry directed research at the University of Arkansas focused on protein targeting, protein production technologies, and development of antibody-based therapies to treat methamphetamine addiction. As a co-founder of InterveXion and in his role as VP, Dr. Henry brings experience in molecular biology, protein manufacturing technology, and molecular engineering of proteins. Dr. Henry supports interactions with FDA, manufacturing and testing of InterveXion’s protein therapies, and oversight of these therapies for pre-clinical and human clinical trials.
Misty Stevens, Ph.D., MBA
Misty Ward Stevens, PhD, MBA is Operations Director for InterveXion with experience in protein biochemistry and cell culture, plus entrepreneurship. These skills allow her to conduct and oversee science operations at InterveXion and coordinate activities with commercial laboratories conducting the antibody manufacturing and testing. Furthermore, she has been involved in grant writing and administration, business plan and budget maturity, and patent filings.
Gerald A. Damerow
Chief Financial Officer
A former Ernst & Young partner, Gerald Damerow, CPA, serves as acting Chief Financial Officer. He is also a retired Associate Director of the UAMS BioVentures business accelerator.